|
Gene: DTYMK |
Gene summary for DTYMK |
Gene summary. |
Gene information | Species | Human | Gene symbol | DTYMK | Gene ID | 1841 |
Gene name | deoxythymidylate kinase | |
Gene Alias | CDC8 | |
Cytomap | 2q37.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P23919 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1841 | DTYMK | LZE2T | Human | Esophagus | ESCC | 1.06e-02 | 3.76e-01 | 0.082 |
1841 | DTYMK | LZE4T | Human | Esophagus | ESCC | 1.53e-05 | 2.22e-01 | 0.0811 |
1841 | DTYMK | LZE7T | Human | Esophagus | ESCC | 7.41e-06 | 3.28e-01 | 0.0667 |
1841 | DTYMK | LZE8T | Human | Esophagus | ESCC | 3.65e-09 | 3.95e-01 | 0.067 |
1841 | DTYMK | LZE20T | Human | Esophagus | ESCC | 4.42e-03 | 1.69e-01 | 0.0662 |
1841 | DTYMK | LZE22T | Human | Esophagus | ESCC | 8.42e-03 | 5.69e-01 | 0.068 |
1841 | DTYMK | LZE24T | Human | Esophagus | ESCC | 6.38e-12 | 4.34e-01 | 0.0596 |
1841 | DTYMK | LZE21T | Human | Esophagus | ESCC | 7.19e-03 | 4.10e-01 | 0.0655 |
1841 | DTYMK | LZE6T | Human | Esophagus | ESCC | 3.94e-10 | 4.39e-01 | 0.0845 |
1841 | DTYMK | P1T-E | Human | Esophagus | ESCC | 3.09e-08 | 4.71e-01 | 0.0875 |
1841 | DTYMK | P2T-E | Human | Esophagus | ESCC | 3.38e-34 | 8.15e-01 | 0.1177 |
1841 | DTYMK | P4T-E | Human | Esophagus | ESCC | 1.32e-28 | 8.27e-01 | 0.1323 |
1841 | DTYMK | P5T-E | Human | Esophagus | ESCC | 6.72e-32 | 8.02e-01 | 0.1327 |
1841 | DTYMK | P8T-E | Human | Esophagus | ESCC | 1.04e-28 | 5.83e-01 | 0.0889 |
1841 | DTYMK | P9T-E | Human | Esophagus | ESCC | 6.89e-21 | 5.68e-01 | 0.1131 |
1841 | DTYMK | P10T-E | Human | Esophagus | ESCC | 5.22e-39 | 9.36e-01 | 0.116 |
1841 | DTYMK | P11T-E | Human | Esophagus | ESCC | 4.75e-14 | 5.35e-01 | 0.1426 |
1841 | DTYMK | P12T-E | Human | Esophagus | ESCC | 5.44e-25 | 5.43e-01 | 0.1122 |
1841 | DTYMK | P15T-E | Human | Esophagus | ESCC | 3.32e-33 | 9.25e-01 | 0.1149 |
1841 | DTYMK | P16T-E | Human | Esophagus | ESCC | 7.26e-24 | 6.20e-01 | 0.1153 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00091483 | Esophagus | ESCC | pyrimidine nucleoside triphosphate biosynthetic process | 15/8552 | 19/18723 | 3.29e-03 | 1.35e-02 | 15 |
GO:000616519 | Esophagus | ESCC | nucleoside diphosphate phosphorylation | 59/8552 | 99/18723 | 3.65e-03 | 1.49e-02 | 59 |
GO:000939412 | Esophagus | ESCC | 2'-deoxyribonucleotide metabolic process | 27/8552 | 40/18723 | 4.39e-03 | 1.73e-02 | 27 |
GO:00091163 | Esophagus | ESCC | nucleoside metabolic process | 39/8552 | 62/18723 | 4.68e-03 | 1.82e-02 | 39 |
GO:00062213 | Esophagus | ESCC | pyrimidine nucleotide biosynthetic process | 21/8552 | 30/18723 | 6.17e-03 | 2.27e-02 | 21 |
GO:00436275 | Esophagus | ESCC | response to estrogen | 45/8552 | 75/18723 | 8.75e-03 | 3.08e-02 | 45 |
GO:00092653 | Esophagus | ESCC | 2'-deoxyribonucleotide biosynthetic process | 10/8552 | 12/18723 | 8.94e-03 | 3.12e-02 | 10 |
GO:00463853 | Esophagus | ESCC | deoxyribose phosphate biosynthetic process | 10/8552 | 12/18723 | 8.94e-03 | 3.12e-02 | 10 |
GO:000921912 | Esophagus | ESCC | pyrimidine deoxyribonucleotide metabolic process | 17/8552 | 24/18723 | 1.13e-02 | 3.81e-02 | 17 |
GO:000675312 | Liver | Cirrhotic | nucleoside phosphate metabolic process | 190/4634 | 497/18723 | 1.10e-11 | 6.96e-10 | 190 |
GO:000911712 | Liver | Cirrhotic | nucleotide metabolic process | 187/4634 | 489/18723 | 1.55e-11 | 9.63e-10 | 187 |
GO:001003812 | Liver | Cirrhotic | response to metal ion | 150/4634 | 373/18723 | 2.27e-11 | 1.37e-09 | 150 |
GO:000913212 | Liver | Cirrhotic | nucleoside diphosphate metabolic process | 58/4634 | 124/18723 | 7.88e-08 | 2.33e-06 | 58 |
GO:004693912 | Liver | Cirrhotic | nucleotide phosphorylation | 49/4634 | 101/18723 | 1.95e-07 | 5.07e-06 | 49 |
GO:000616512 | Liver | Cirrhotic | nucleoside diphosphate phosphorylation | 47/4634 | 99/18723 | 7.63e-07 | 1.61e-05 | 47 |
GO:004668612 | Liver | Cirrhotic | response to cadmium ion | 34/4634 | 68/18723 | 6.04e-06 | 9.74e-05 | 34 |
GO:00091232 | Liver | Cirrhotic | nucleoside monophosphate metabolic process | 36/4634 | 76/18723 | 1.55e-05 | 2.11e-04 | 36 |
GO:00196922 | Liver | Cirrhotic | deoxyribose phosphate metabolic process | 23/4634 | 42/18723 | 2.97e-05 | 3.75e-04 | 23 |
GO:00093942 | Liver | Cirrhotic | 2'-deoxyribonucleotide metabolic process | 22/4634 | 40/18723 | 4.04e-05 | 4.82e-04 | 22 |
GO:00092622 | Liver | Cirrhotic | deoxyribonucleotide metabolic process | 23/4634 | 44/18723 | 7.87e-05 | 8.61e-04 | 23 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012325 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa002405 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
hsa0123212 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa0024012 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
hsa01232 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
hsa00240 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
hsa012321 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
hsa002401 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
hsa002402 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
hsa012322 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa002403 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
hsa012323 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa012324 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa002404 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
hsa0123211 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa0024011 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
hsa0123221 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
hsa0024021 | Oral cavity | LP | Pyrimidine metabolism | 28/2418 | 58/8465 | 1.12e-03 | 5.02e-03 | 3.24e-03 | 28 |
hsa0123231 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
hsa0024031 | Oral cavity | LP | Pyrimidine metabolism | 28/2418 | 58/8465 | 1.12e-03 | 5.02e-03 | 3.24e-03 | 28 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DTYMK | SNV | Missense_Mutation | c.212N>C | p.Leu71Pro | p.L71P | P23919 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
DTYMK | deletion | Frame_Shift_Del | novel | c.395delT | p.Phe132SerfsTer37 | p.F132Sfs*37 | P23919 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
DTYMK | SNV | Missense_Mutation | c.259T>A | p.Leu87Met | p.L87M | P23919 | protein_coding | deleterious(0.01) | probably_damaging(0.971) | TCGA-AG-A016-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | SD | |
DTYMK | SNV | Missense_Mutation | rs766664417 | c.434N>T | p.Ala145Val | p.A145V | P23919 | protein_coding | deleterious(0.04) | benign(0.054) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
DTYMK | SNV | Missense_Mutation | c.575N>A | p.Arg192His | p.R192H | P23919 | protein_coding | tolerated(0.36) | benign(0) | TCGA-A5-A0GB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
DTYMK | SNV | Missense_Mutation | rs149828739 | c.449N>A | p.Arg150His | p.R150H | P23919 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DTYMK | SNV | Missense_Mutation | novel | c.620N>C | p.Leu207Pro | p.L207P | P23919 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
DTYMK | SNV | Missense_Mutation | novel | c.478N>A | p.Ala160Thr | p.A160T | P23919 | protein_coding | deleterious(0) | possibly_damaging(0.448) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
DTYMK | SNV | Missense_Mutation | c.242N>T | p.Pro81Leu | p.P81L | P23919 | protein_coding | deleterious(0.05) | benign(0.19) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
DTYMK | SNV | Missense_Mutation | rs139227304 | c.427N>T | p.Arg143Trp | p.R143W | P23919 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D1-A1O7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1841 | DTYMK | KINASE | 5-FU | FLUOROURACIL | 15067352 | |
1841 | DTYMK | KINASE | zidovudine | ZIDOVUDINE | 22960662 | |
1841 | DTYMK | KINASE | D4T | STAVUDINE | 15134538 | |
1841 | DTYMK | KINASE | ETHANOL | ALCOHOL | 11923581 |
Page: 1 |